TEMPE, Ariz., Sept. 12, 2008 (GLOBE NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today the publication of positive results from pre-clinical studies of AZX100 in the management of excessive dermal scarring. There are approximately 21 million surgical procedures performed annually in the U.S. that can result in some form of dermal scarring.
